{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:37:47Z","timestamp":1780580267630,"version":"3.54.1"},"reference-count":136,"publisher":"FapUNIFESP (SciELO)","issue":"2 suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An. Bras. Dermatol."],"DOI":"10.1590\/abd1806-4841.2019940206","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:51:24Z","timestamp":1559418684000},"page":"20-32","source":"Crossref","is-referenced-by-count":35,"title":["Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology"],"prefix":"10.1590","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-4790","authenticated-orcid":false,"given":"Adriana Maria","family":"Porro","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9324-3703","authenticated-orcid":false,"given":"G\u00fcnter","family":"Hans Filho","sequence":"additional","affiliation":[{"name":"Universidade Federal de Mato Grosso do Sul, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3650-4254","authenticated-orcid":false,"given":"Claudia Giuli","family":"Santi","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2019,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2340\/00015555-2611","article-title":"Mortality and cause of death in Israeli patients with pemphigus","volume":"97","author":"Kridin K","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/bjd.14463","article-title":"Comorbidities and inpatient mortality for pemphigus in the USA","volume":"174","author":"Hsu DY","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00281-015-0541-1","article-title":"Immune response in pemphigus and beyond: progresses and emerging concepts","volume":"38","author":"Di Zenzo G","year":"2016","journal-title":"Semin Immunopathol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1172\/JCI5252","article-title":"Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris","volume":"103","author":"Mahoney MG","year":"1999","journal-title":"J Clin Invest"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2230.2011.04092.x","article-title":"The pathogenic role of autoantibodies in pemphigus vulgaris","volume":"36","author":"Pan M","year":"2011","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2011.01.013","article-title":"Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis)","volume":"29","author":"Joly P","year":"2011","journal-title":"Clin Dermatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/exd.12229","article-title":"Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris","volume":"22","author":"Amber KT","year":"2013","journal-title":"Exp Dermatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin K","year":"2018","journal-title":"Immunol Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(05)66829-8","article-title":"Pemphigus","volume":"366","author":"Bystryn JC","year":"2005","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches","volume":"54","author":"Pollmann R","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers CM","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.clindermatol.2015.11.006","article-title":"Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica","volume":"34","author":"Broussard KC","year":"2016","journal-title":"Clin Dermatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0733-8635(18)30241-9","article-title":"Pemphigus vulgaris and vegetans","volume":"11","author":"Becker BA","year":"1993","journal-title":"Dermatol Clin"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clindermatol.2011.03.013","article-title":"Immunosuppressive therapy for autoimmune bullous diseases","volume":"30","author":"Meurer M","year":"2012","journal-title":"Clin Dermatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","article-title":"The adjuvant therapy of pemphigus. An update","volume":"132","author":"Bystryn JC","year":"1996","journal-title":"Arch Dermatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jdv.12772","article-title":"Pemphigus. S2 guideline for diagnosis and treatment-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"29","author":"Hertl M","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.intimp.2017.10.027","article-title":"Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?","volume":"53","author":"Tavakolpour S","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.clindermatol.2013.01.005","article-title":"Pemphigus: Associations and management guidelines: Facts and controversies","volume":"31","author":"Ruocco E","year":"2013","journal-title":"Clin Dermatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.15930","article-title":"British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017","volume":"177","author":"Harman KE","year":"2017","journal-title":"Br J Dermatol"},{"key":"ref20","first-page":"329","article-title":"Pulse therapy and its modifications in pemphigus: a six year study","volume":"69","author":"Rao PN","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi C","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0190-9622(82)70111-2","article-title":"Death in pemphigus","volume":"7","author":"Ahmed AR","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.det.2011.07.001","article-title":"Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus","volume":"29","author":"Frew JW","year":"2011","journal-title":"Dermatol Clin"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaad.2015.04.038","article-title":"The role of adjuvant therapy in pemphigus: A systematic review and meta- analysis","volume":"73","author":"Atzmony L","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1172\/JCI200318384","article-title":"Azathioprine: old drug, new actions","volume":"111","author":"Maltzman JS","year":"2003","journal-title":"J Clin Invest"},{"key":"ref26","first-page":"1285","article-title":"Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris","volume":"27","author":"Chams-Davatchi C","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1468-3083.2010.03753.x","article-title":"High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study","volume":"25","author":"Chaidemenos G","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/1346-8138.12486","article-title":"Japanese guidelines for the management of pemphigus","volume":"41","author":"Amagai M","year":"2014","journal-title":"J Dermatol"},{"key":"ref29","first-page":"353","article-title":"Mycophenolate mofetil-a new atheropreventive drug?","volume":"71","author":"Olejarz W","year":"2014","journal-title":"Acta Pol Pharm"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s12325-016-0343-4","article-title":"Management of Pemphigus Vulgaris","volume":"33","author":"Cholera M","year":"2016","journal-title":"Adv Ther"},{"key":"ref31","first-page":"210","article-title":"Mycophenolate mofetil as a first-line steroid sparing agent in the treatment of pemphigus vulgaris","volume":"12","author":"Vyas N","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jaad.2010.04.039","article-title":"A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus","volume":"64","author":"Martin LK","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2010.91","article-title":"Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo controlled trial","volume":"130","author":"Beissert S","year":"2010","journal-title":"J Invest Dermatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immuneglobulin","volume":"355","author":"Ahmed AR","year":"2006","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming R","year":"2008","journal-title":"J Invest Dermatol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jaad.2015.11.008","article-title":"Future therapies for pemphigus vulgaris:Rituximab and beyond","volume":"74","author":"Huang A","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang HH","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly P","year":"2017","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jamadermatol.2014.2421","article-title":"First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids","volume":"151","author":"Ingen-Housz-Oro S","year":"2015","journal-title":"JAMA Dermatol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review","volume":"54","author":"Tavakolpour S","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini G","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan K","year":"2014","journal-title":"JAMA Dermatol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high and low dose rituximab treatments in pemphigus patients:a randomized comparative observer blinded study","volume":"170","author":"Kanwar AJ","year":"2014","journal-title":"Br J Dermatol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/jdv.12678","article-title":"An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab","volume":"29","author":"Amber KT","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly P","year":"2007","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4103\/0378-6323.136832","article-title":"Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus","volume":"80","author":"Londhe PJ","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up","volume":"34","author":"Ahmed AR","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1365-2133.2011.10732.x","article-title":"Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris","volume":"166","author":"Behzad M","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jaad.2006.07.019","article-title":"Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2)","volume":"56","author":"Graves JE","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients","volume":"148","author":"Lunardon L","year":"2012","journal-title":"Arch Dermatol"},{"key":"ref51","article-title":"Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts","author":"Murrell DF","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaad.2012.08.010","article-title":"Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients","volume":"68","author":"Leshem YA","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2230.2009.03450.x","article-title":"Corticosteroid \/cyclophosphamide pulse treatment in south African patients with pemphigus","volume":"35","author":"Shaik F","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-015-0353-6","article-title":"Pemphigus Vulgaris: An Evidence-Based Treatment Update","volume":"75","author":"Zhao CY","year":"2015","journal-title":"Drugs"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/ced.12073","article-title":"Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris","volume":"38","author":"Sharma VK","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1610-0378.2005.04747.x","article-title":"Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study","volume":"3","author":"Rose E","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4103\/0378-6323.55390","article-title":"Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris","volume":"75","author":"Sethy PK","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/0378-6323.104672","article-title":"Assessment of the therapeutic benefit of dexamethasone cyclophosphamide pulse versus only oral cyclophosphamide in phase II of the dexamethasone cyclophosphamide pulse therapy: a preliminary prospective randomized controlled study","volume":"79","author":"Parmar NV","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","article-title":"Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid","volume":"161","author":"G\u00fcrcan HM","year":"2009","journal-title":"Br J Dermatol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1684\/ejd.2011.1611","article-title":"Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris","volume":"22","author":"Baum S","year":"2012","journal-title":"Eur J Dermatol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjd.12474","article-title":"Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients","volume":"169","author":"Tran KD","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","article-title":"Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data","volume":"10","author":"G\u00fcrcan HM","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1159\/000448028","article-title":"Efficacy of Dapsone in the treatment of pemphigus vulgaris: a single-center case study","volume":"232","author":"Baum S","year":"2016","journal-title":"Dermatology"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00128071-200708020-00004","article-title":"Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris","volume":"8","author":"Olszewska M","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.transci.2016.12.017","article-title":"Mechanisms of action of intravenous immunoglobulin","volume":"56","author":"Chaigne B","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ajd.12422","article-title":"IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects","volume":"57","author":"Svecova D","year":"2016","journal-title":"Australas J Dermatol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai M","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1684\/ejd.2014.2483","article-title":"Pemphigus vulgaris: approach to treatment","volume":"25","author":"Sinha AA","year":"2015","journal-title":"Eur J Dermatol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000090659","article-title":"Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein- reactive autoantibodies by immunoadsorption","volume":"212","author":"Eming R","year":"2006","journal-title":"Dermatology"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","article-title":"Immunoadsorption in dermatology","volume":"16","author":"Meyersburg D","year":"2012","journal-title":"Ther Apher Dial"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2230.2004.01499.x","article-title":"Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris","volume":"29","author":"Gach JE","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell DF","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/archderm.144.5.682","article-title":"Kinetics of response to conventional treatment in patients with pemphigus vulgaris","volume":"144","author":"Czernik A","year":"2008","journal-title":"Arch Dermatol"},{"key":"ref74","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006263.pub2","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","author":"Martin LK","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0190-9622(00)90213-5","article-title":"Patterns of remission in pemphigus vulgaris","volume":"42","author":"Herbst A","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaad.2013.05.016","article-title":"Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids","volume":"69","author":"Almugairen N","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40257-014-0101-9","article-title":"Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus: A Systematic Review and Meta- Analysis","volume":"15","author":"Atzmony L","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0190-9622(89)70079-7","article-title":"Endemic pemphigus foliaceus (fogo selvagem). I. Clinical features and immunopathology","volume":"20","author":"Diaz LA","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"ref79","series-title":"Dermatology","first-page":"461","volume-title":"Pemphigus","volume":"1","author":"Amagai M","year":"2012","edition":"2nd ed"},{"key":"ref80","series-title":"Tropical Dermatology","first-page":"427","volume-title":"Fogo Selvagem (Endemic Pemphigus Foliaceus)","author":"Hans-Filho G","year":"2017","edition":"2nd ed"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0738-081X(99)00014-0","article-title":"Endemic pemphigus foliaceus (fogo selvagem) - 1998. The Cooperative Group on Fogo Selvagem Research","volume":"17","author":"Hans-Filho G","year":"1999","journal-title":"Clin Dermatol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archderm.1959.01560220001001","article-title":"The disease called wildfire","volume":"80","author":"Counter CE","year":"1959","journal-title":"Arch Dermatol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1523-1747.ep13070394","article-title":"Endemic pemphigus foliaceus (Fogo selvagem): II. Current and historic epidemiologic studies","volume":"92","author":"Diaz LA","year":"1989","journal-title":"J Invest Dermatol"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1365-2133.1988.tb02590.x","article-title":"South American pemphigus: study of an epidemic in El Bagre and Nechi, Colombia 1982 to 1986","volume":"118","author":"Robledo MA","year":"1988","journal-title":"Br J Dermatol"},{"key":"ref85","series-title":"P\u00eanfigo foli\u00e1ceo (fogo selvagem). Aspectos cl\u00ednicos e epidemiol\u00f3gicos","author":"Campos JA","year":"1942"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/1523-1747.ep12612836","article-title":"Comparative epidemiologic of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women","volume":"104","author":"Bastuji-Garin S","year":"1995","journal-title":"J Invest Dermatol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/1523-1747.ep12298213","article-title":"An active focus of high prevalence of fogo selvagem on an Amerindian reservation in Brazil. Cooperative Group on Fogo Selvagem Research","volume":"107","author":"Hans-Filho G","year":"1996","journal-title":"J Invest Dermatol"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1087-0024.2004.00833.x","article-title":"Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem)","volume":"9","author":"Aoki V","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2004.23438.x","article-title":"Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to fogo selvagem","volume":"123","author":"Diaz LA","year":"2004","journal-title":"J Invest Dermatol"},{"key":"ref90","series-title":"Tropical Dermatology","first-page":"421","volume-title":"Fogo Selvagem (endemic pemphigus foliaceus)","author":"Rivitti EA","year":"2006"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.4049\/jimmunol.1200842","article-title":"Cutting Edge: Brazilian Pemphigus Foliaceus Anti-Desmoglein 1 Autoantibodies Cross- React with Sand Fly Salivary LJM11 Antigen","volume":"189","author":"Qian Y","year":"2012","journal-title":"J Immunol"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.2.6049.1423","article-title":"Pemphigus foliaceus induced by penicillamine","volume":"2","author":"Marsden RA","year":"1976","journal-title":"Br Med J"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clindermatol.2011.01.016","article-title":"Drug-induced pemphigus","volume":"29","author":"Brenner S","year":"2011","journal-title":"Clin Dermatol"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1399-0039.1997.tb02707.x","article-title":"An epitope in the third hypervariable region of the DRB1 gene is involved in the susceptibility to endemic pemphigus foliaceus (fogo selvagem) in three different Brazilian populations","volume":"49","author":"Moraes ME","year":"1997","journal-title":"Tissue Antigens"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.humimm.2013.06.008","article-title":"Both qualitative and quantitative genetic variation of MHC class II molecules may influence susceptibility to autoimmune diseases: The case of endemic pemphigus foliaceus","volume":"74","author":"Piovezan BZ","year":"2013","journal-title":"Hum Immunol"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0092-8674(91)90360-B","article-title":"Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion","volume":"67","author":"Amagai M","year":"1991","journal-title":"Cell"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/1346-8138.12675","article-title":"Update on fogo selvagem, an endemic form of pemphigus foliaceus","volume":"42","author":"Aoki V","year":"2015","journal-title":"J Dermatol"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1038\/jid.2012.369","article-title":"Endemic Pemphigus Foliaceus: Towards Understanding Autoimmune Mechanisms of Disease Development","volume":"132","author":"Di Zenzo G","year":"2012","journal-title":"J Invest Dermatol"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1172\/JCI115968","article-title":"Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic","volume":"90","author":"Amagai M","year":"1992","journal-title":"J Clin Invest"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaut.2017.12.017","article-title":"Pathogenic IgG4 autoantibodies from endemic pemphigus foliaceus recognize a desmoglein-1 conformational epitope","volume":"89","author":"Evangelista F","year":"2018","journal-title":"J Autoimmun"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaut.2008.08.003","article-title":"Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: A paradigm of human autoimmunity","volume":"31","author":"Culton DA","year":"2008","journal-title":"J Autoimmun"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1590\/abd1806-4841.20188235","article-title":"Fogo selvagem: endemic pemphigus foliaceus","volume":"93","author":"Hans-Filho G","year":"2018","journal-title":"An Bras Dermatol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00418-008-0420-0","article-title":"The desmosome and pemphigus","volume":"130","author":"Waschke J","year":"2008","journal-title":"Histochem Cell Biol"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3181\/00379727-127-32626","article-title":"Immunofluorescent studies of autoantibodies to intercellular areas of epithelia in Brazilian Pemphigus Foliaceus","volume":"127","author":"Beutner EH","year":"1968","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1600-0625.2005.00367.x","article-title":"Mechanisms of blister induction by autoantibodies","volume":"14","author":"Sitaru C","year":"2005","journal-title":"Exp Dermatol"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/j.1365-2133.2012.11173.x","article-title":"Ultrastructure of acantholysis in pemphigus foliaceus re-examined from the current perspective","volume":"167","author":"van der Wier G","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/1523-1747.ep12277362","article-title":"Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB\/c mice by passive transfer","volume":"85","author":"Roscoe JT","year":"1985","journal-title":"J Invest Dermatol"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM200007063430104","article-title":"The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil","volume":"343","author":"Warren SJ","year":"2000","journal-title":"N Engl J Med"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1523-1747.2003.12017.x","article-title":"The Role of Subclass Switching in the Pathogenesis of Endemic Pemphigus Foliaceus","volume":"120","author":"Warren SJ","year":"2003","journal-title":"J Invest Dermatol"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1084\/jem.20022031","article-title":"The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem)","volume":"197","author":"Li N","year":"2003","journal-title":"J Exp Med"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jdermsci.2016.12.010","article-title":"Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to incrase blistering by p38MAPK-dependent desmoglein 1 clustering","volume":"85","author":"Yoshida K","year":"2017","journal-title":"J Dermatol Sci"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/08916934.2011.606444","article-title":"Pemphigus autoimmunity: hypotheses and realities","volume":"45","author":"Grando SA","year":"2012","journal-title":"Autoimmunity"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.jid.5701121","article-title":"The IgM anti-desmoglein 1 response distinguishes Brazilian pemphigus foliaceus (fogo selvagem) from other forms of pemphigus","volume":"128","author":"Diaz LA","year":"2008","journal-title":"J Invest Dermatol"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/jid.2008.189","article-title":"Development of na IgG4-based predictor of endemic pemphigus foliaceus (fogo selvagem)","volume":"129","author":"Qaqish BF","year":"2009","journal-title":"J Invest Dermatol"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/sj.jid.5700388","article-title":"Prevalence of anti-desmogleina-3 antibodies in endemic regions of fogo selvagem in Brazil","volume":"126","author":"Hilario-Vargas J","year":"2006","journal-title":"J Invest Dermatol"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1128\/CDLI.10.5.741-743.2003","article-title":"High levels of interleukin-1 in patiens with endemic pemphigus foliaceus","volume":"10","author":"Rocha-Rodrigues DB","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s10875-012-9679-y","article-title":"Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus","volume":"32","author":"Chriguer RS","year":"2012","journal-title":"J Clin Immunol"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-4362.2001.01083.x","article-title":"TNF-a end IL-6 are mediator in the blisterin process of pemphigus","volume":"40","author":"L\u00f3pez-Robles E","year":"2001","journal-title":"Int J Dermatol"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2017.00978","article-title":"Cytokine and chemokines alterations in the form of pemphigus folicaceus (fogo selvagem)","volume":"8","author":"Tim\u00f3teo RP","year":"2017","journal-title":"Front Immunol"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdermsci.2008.09.008","article-title":"Lesional Th 17 cells in pemphigus vulgaris and pemphigus foliaceus","volume":"53","author":"Arakawa M","year":"2009","journal-title":"J Dermatol Sci"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2334\/josnusd.50.213","article-title":"Nikolsky's sign revisited","volume":"50","author":"Juneja M","year":"2008","journal-title":"Journal of Oral Science"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.det.2011.03.012","article-title":"Diagnosis and clinical features of pemphigus foliaceus","volume":"29","author":"James KA","year":"2011","journal-title":"Dermatol Clin"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1067\/mjd.2000.110400","article-title":"Transplacental passage of maternal pemphigus foliaceus autoantibodies induces neonatal pemphigus","volume":"43","author":"Avalos-D\u00edaz E","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/pde.12859","article-title":"Neonatal Autoimmune Blistering Disease: A Systematic Review","volume":"33","author":"Zhao CY","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.15537\/smj.2015.9.12270","article-title":"Pemphigus and pregnancy","volume":"36","author":"Lin L","year":"2015","journal-title":"Saudi Med J"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jpeds.2012.04.036","article-title":"Neonatal pemphigus foliaceus","volume":"161","author":"Lorente Lavirgen AI","year":"2012","journal-title":"J Pediatr"},{"key":"ref127","series-title":"Fitzpatrick's Dermatology in General Medicine","first-page":"586","volume-title":"Pemphigus","volume":"1","author":"Payne AS","year":"2012","edition":"8th ed"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0738-081X(98)00010-8","article-title":"Drug-induced pemphigus","volume":"16","author":"Brenner S","year":"1998","journal-title":"Clin Dermatol"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1590\/abd1806-4841.20143221","article-title":"Immunofluorescence testing in the diagnosis of autoimmune blistering diseases: overview of 10-year experience","volume":"89","author":"Arbache ST","year":"2014","journal-title":"An Bras Dermatol"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clindermatol.2011.03.014","article-title":"Current therapy of the pemphigus group","volume":"30","author":"Kasperkiewicz M","year":"2012","journal-title":"Clin Dermatol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jaad.2004.02.013","article-title":"Management of autoimmune bullous diseases: Pharmacology and therapeutics","volume":"51","author":"Mutasim DF","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00403-009-1024-9","article-title":"Immunoadsorption in dermatology","volume":"302","author":"Schmidt E","year":"2010","journal-title":"Arch Dermatol Res"},{"key":"ref133","series-title":"Inicial management of pemphigus vulgaris and pemphigus foliaceus","author":"Hertl M","year":"2017"},{"key":"ref134","series-title":"Evaluation of Chemotherapeutic Agents","first-page":"196","volume-title":"The Clinical Evaluation of Chemotherapeutic Agents in Cancer","author":"Karnofsky DA","year":"1949"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clindermatol.2011.03.017","article-title":"Severity score indexes for blistering diseases","volume":"30","author":"Daniel BS","year":"2012","journal-title":"Clin Dermatol"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.det.2011.03.015","article-title":"Objective scoring systems for disease activity in autoimmune bullous disease","volume":"29","author":"Sebaratnam DF","year":"2011","journal-title":"Dermatol Clin"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abd\/v94n2s1\/0365-0596-abd-94-02-s1-0020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:46Z","timestamp":1747666846000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0365-05962019000700020&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":136,"journal-issue":{"issue":"2 suppl 1","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["S0365-05962019000700020"],"URL":"https:\/\/doi.org\/10.1590\/abd1806-4841.2019940206","relation":{},"ISSN":["1806-4841","0365-0596"],"issn-type":[{"value":"1806-4841","type":"electronic"},{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}